3,010 Shares in Novartis AG (NYSE:NVS) Acquired by J Hagan Capital Inc.

J Hagan Capital Inc. acquired a new position in shares of Novartis AG (NYSE:NVS - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 3,010 shares of the company's stock, valued at approximately $336,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Continuum Advisory LLC increased its holdings in shares of Novartis by 10.3% during the fourth quarter. Continuum Advisory LLC now owns 1,021 shares of the company's stock worth $99,000 after buying an additional 95 shares in the last quarter. Intergy Private Wealth LLC grew its position in Novartis by 3.9% during the 1st quarter. Intergy Private Wealth LLC now owns 2,757 shares of the company's stock worth $307,000 after acquiring an additional 104 shares during the last quarter. Keudell Morrison Wealth Management increased its holdings in Novartis by 3.8% in the 1st quarter. Keudell Morrison Wealth Management now owns 2,828 shares of the company's stock worth $315,000 after purchasing an additional 104 shares in the last quarter. D Orazio & Associates Inc. raised its position in Novartis by 2.9% in the first quarter. D Orazio & Associates Inc. now owns 3,795 shares of the company's stock valued at $423,000 after purchasing an additional 108 shares during the last quarter. Finally, Opal Wealth Advisors LLC boosted its stake in shares of Novartis by 4.7% during the first quarter. Opal Wealth Advisors LLC now owns 2,515 shares of the company's stock valued at $280,000 after purchasing an additional 112 shares in the last quarter. Institutional investors own 13.12% of the company's stock.

Novartis Trading Up 0.2%

Shares of Novartis stock traded up $0.21 during midday trading on Monday, reaching $122.11. The company had a trading volume of 1,003,320 shares, compared to its average volume of 1,584,830. The stock has a fifty day moving average price of $115.08 and a 200 day moving average price of $109.07. Novartis AG has a fifty-two week low of $96.06 and a fifty-two week high of $125.41. The firm has a market cap of $257.95 billion, a PE ratio of 19.08, a P/E/G ratio of 1.68 and a beta of 0.59. The company has a debt-to-equity ratio of 0.56, a current ratio of 0.79 and a quick ratio of 0.61.

Novartis (NYSE:NVS - Get Free Report) last released its earnings results on Tuesday, April 29th. The company reported $2.28 EPS for the quarter, topping the consensus estimate of $2.12 by $0.16. Novartis had a return on equity of 39.44% and a net margin of 24.70%. The business had revenue of $13.23 billion during the quarter, compared to analysts' expectations of $12.92 billion. During the same quarter last year, the firm posted $1.80 earnings per share. The firm's revenue was up 11.9% on a year-over-year basis. On average, equities analysts anticipate that Novartis AG will post 8.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, BNP Paribas raised Novartis to a "strong-buy" rating in a research note on Tuesday, April 15th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $123.67.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.